The Daily Buyout
~$375MreportedTake-privateHealthcare & Life SciencesCompleted

Altaris completes take-private of Simulations Plus

Simulations Plus, the Nasdaq-listed developer of model-informed and AI-accelerated drug development software, announced the completion of its acquisition by affiliates of healthcare-focused investment firm Altaris. The transaction was originally announced on June 16, 2026, and shares of the company were converted at the effective time of the merger.

Why it matters: Another listed life-sciences software name leaves the public markets as healthcare-specialist buyout firms keep hunting for niche, high-margin pharma tools.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals

$5.8BTake-privateHealthcare & Life SciencesOct 7, 2026

CD&R and McKesson to take Option Care Health private for $5.8B

Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.

Read at SEC EDGARFree
$2BStrategic acquisitionHealthcare & Life SciencesOct 6, 2026

Shionogi pays $2B for rare disease biotech IntraBio

Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.

Read at BioPharma DiveFree